MedTrace Logo

Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma

NCT02645409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-02-25

Study results available
· View outcomes & findings →

Summary

Primary

• To explore the use of OTL38 and fluorescence imaging to detect RCC in partial nephrectomy at the margins of resection, and in lymph node(s) or other metastases during radical nephrectomy.

Conditions

Interventions

DRUG

OTL38

OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.

DEVICE

Intraoperative fluorescence imaging system

Sponsors & Collaborators

  • Chandru Sundaram

    lead OTHER

Principal Investigators

  • Chandru P. Sundaram, MD · Indiana University School of Medicine, Indiana University Simon Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-29
Primary Completion
2018-03-20
Completion
2019-04-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02645409 on ClinicalTrials.gov